Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891874 | 0.89 | ALDH1A1 (0.36) | ALDH1A1LMNAKDM4ECYP1A2ALOX15 | |
| SCHEMBL9892856 | 0.73 | TP53 (0.38) | ALDH1A1LMNAKDM4ENPC1RAB9A | |
| SCHEMBL12384446 | 0.70 | ALDH1A1 (0.48) | ALDH1A1LMNAKDM4ENPC1RAB9A | |
| SCHEMBL3429323 | 0.69 | ALDH1A1 (0.43) | ALDH1A1LMNAKDM4ENPC1RAB9A | |
| SCHEMBL3429330 | 0.69 | ALDH1A1 (0.43) | ALDH1A1LMNAKDM4ENPC1RAB9A | |
| SCHEMBL16480385 | 0.68 | ALDH1A1 (0.42) | ALDH1A1LMNAKDM4ENPC1RAB9A | |
| SCHEMBL28481811 | 0.67 | ALDH1A1 (0.38) | ALDH1A1LMNAKDM4ENPC1RAB9A | |
| SCHEMBL9893174 | 0.67 | TP53 (0.46) | ALDH1A1LMNAKDM4EMAPTCYP1A2 | |
| SCHEMBL9103345 | 0.64 | FKBP1A (0.47) | ALDH1A1KDM4ECYP1A2KMT2AHTT | |
| SCHEMBL9103351 | 0.64 | FKBP1A (0.47) | ALDH1A1KDM4ECYP1A2KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 1724/4885LMNA 4544/4885KDM4E 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.